Study Reveals Waning Japanese Encephalitis Immunity May Increase Severity of Dengue Infections in South Asia
A new study conducted in Nepal suggests that waning immunity against the Japanese Encephalitis Virus (JEV) can predispose individuals to more severe dengue fever. Both viruses belong to the genus Orthoflavivirus, and cross-reactivity between their antibodies can lead to antibody-dependent enhancement. This phenomenon occurs when low levels of JEV antibodies facilitate the entry of the dengue virus into cells, worsening the disease. The findings highlight the importance of timely JEV vaccine boosters, especially in regions like India where both diseases are prevalent, to protect against severe outcomes and manage the changing epidemiology of dengue.
Key Points
- JEV and Dengue are both mosquito-borne diseases belonging to the same viral genus, Orthoflavivirus.
- Chymase, an enzyme released by mast cells, has been identified as a biomarker for severe dengue.
- Waning JEV immunity can lead to a 3x higher risk of developing severe dengue with warning signs.
- The study underscores the need for integrated infectious disease control and JEV booster strategies in South Asia.
Exam Facts
- Genus: Orthoflavivirus.
- Biomarker for severe dengue: Chymase.
- Study location: Dharan, Nepal (2019-2023).
- JEV vaccine introduced in Nepal in 2006.
Read it. Retain it. Recall it.
Get spaced-repetition flashcards, daily quizzes and offline access — free on Android.